2024
Revisiting the pattern of loss of β-cell function in preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the pattern of loss of β-cell function in preclinical Type 1 Diabetes. Diabetes 2024 PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose control
2023
Quantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2023, 66: 2189-2199. PMID: 37712956, PMCID: PMC10627950, DOI: 10.1007/s00125-023-06011-5.Peer-Reviewed Original ResearchConceptsType 1 diabetesBeta-cell functionInsulin secretionFunctional beta-cell massEarly pre-symptomatic stagesCell functionPre-symptomatic phaseBeta-cell massDisease-modifying interventionsPre-symptomatic stageContinuous glucose monitoringIslet autoimmunityInsulin sensitivityDisease progressionGlucose profilesInvasive measuresPreclinical stageMetabolic testsProgressive lossDiabetesMetabolic changesGlucose monitoringAvailable testsMeasurable changesOGTTIn silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing
Libera A, Toffanin C, Drecogna M, Galderisi A, Pillonetto G, Cobelli C. In silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing. APL Bioengineering 2023, 7: 026105. PMID: 37229215, PMCID: PMC10205143, DOI: 10.1063/5.0145446.Peer-Reviewed Original ResearchIP insulin deliveryInsulin deliveryPeritoneal spaceMeal announcementChronic autoimmune diseaseInsulin kineticsParadigm of treatmentBeta-cell functionIntraperitoneal insulin deliveryType 1 diabetesInpatient trialPeripheral hyperinsulinemiaMacrovascular complicationsGlycemic controlTwo-compartment modelInsulin replacementAutoimmune diseasesInsulin delivery systemsInsulin secretionDaily burdenInsulin pumpAid useCell functionArtificial pancreasDiseaseBeta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatric Endocrinology Diabetes And Metabolism 2023, 29: 1-3. PMID: 37218722, PMCID: PMC10226454, DOI: 10.5114/pedm.2023.126360.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBeta-cell functionType 1 diabetesIslet autoimmunityCell functionFunctional beta-cell massDisease-modifier drugsUnderlying autoimmune processPre-symptomatic phaseBeta-cell massSymptomatic diabetesAutoimmune processClinical onsetSurrogate markerDiabetes progressionC-peptideInsulin secretionModifier drugsEarly changesDiabetesMetabolic changesDysglycaemiaAutoimmunityT1DOnsetModifier treatment
2021
Early Impairment of Insulin Sensitivity, β-Cell Responsiveness, and Insulin Clearance in Youth with Stage 1 Type 1 Diabetes
Galderisi A, Moran A, Evans-Molina C, Martino M, Santoro N, Caprio S, Cobelli C. Early Impairment of Insulin Sensitivity, β-Cell Responsiveness, and Insulin Clearance in Youth with Stage 1 Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2021, 106: 2660-2669. PMID: 34000022, PMCID: PMC8372628, DOI: 10.1210/clinem/dgab344.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell responsivenessInsulin secretion rateΒ-cell functionInsulin sensitivityInsulin clearanceIslet autoantibodiesGlucose toleranceMultiple islet autoantibodiesOGTT glucose concentrationsPlasma insulin AUCImpaired glucose toleranceNormal glucose toleranceGlucose tolerance testType 1 diabetesReduced insulin sensitivityRatio of AUCOral minimal modelLean youthInsulin AUCClinical onsetInsulin levelsDisposition indexPresymptomatic phaseTolerance test
2020
Effect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi A, Cohen N, Calhoun P, Kraemer K, Breton M, Weinzimer S, Cengiz E. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care 2020, 43: 2146-2152. PMID: 32661108, PMCID: PMC7440894, DOI: 10.2337/dc20-0091.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugEquipment and SuppliesFemaleGlycemic ControlHumansHypoglycemic AgentsInsulin Infusion SystemsInsulin, Regular, HumanMaleMealsPostprandial PeriodYoung AdultConceptsControl armPremeal bolusesPostprandial plasma glucose levelsPostprandial blood glucose controlPrimary efficacy outcomeRapid-acting insulinBlood glucose controlPlasma glucose levelsType 1 diabetesLater time pointsSequential mealsEfficacy outcomesPPG levelsSecondary outcomesGlycemic excursionsMeal studyGlucose controlSubcutaneous routeInsulin delivery systemsGlucose levelsGlucose metricsHigh doseStudy daysInsulin absorptionInsulin bolus1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia
SHERR J, BUCKINGHAM B, FORLENZA G, GALDERISI A, EKHLASPOUR L, WADWA R, ZGORSKI M, KINGMAN R, BERGET C, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-1296-p.Peer-Reviewed Original ResearchDiabetes careGlucose targetsEli LillySerious adverse eventsHigh-fat mealRisk of hypoglycemiaAdvisory PanelType 1 diabetesChildren Aged 2MannKind CorporationHybrid closed-loop systemT1D durationAdverse eventsT1D ExchangeFat mealGlucose managementMean glucosePivotal studiesAged 2Bolus challengeDaily exerciseInvestigational deviceDlPercent timeTarget glucose978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
FORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-978-p.Peer-Reviewed Original ResearchDiabetes careMeal bolusEli LillyPercent timeRisk of hypoglycemiaAdvisory PanelType 1 diabetesHigh-fat dinnerMannKind CorporationHybrid closed-loop systemT1D durationGlucose targetsT1D ExchangeGlucose managementPivotal studiesDaily exerciseInvestigational deviceDlTarget glucoseCareLexicon PharmaceuticalsMedtronicBolusLower targetsAdults
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdultsA Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.
Galderisi A, Sherr JL. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. Pediatric Annals 2019, 48: e311-e318. PMID: 31426099, DOI: 10.3928/19382359-20190725-03.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsContinuous glucose monitoringType 1 diabetesGlycemic controlContinuous subcutaneous insulin infusion pumpClosed-loop insulin deliveryIntensive insulin treatmentMultiple daily injectionsChronic medical conditionsLoop insulin deliveryPediatric clinical practiceInsulin infusion pumpDaily injectionsBlood glucoseInsulin treatmentMedical conditionsDiabetes treatmentClinical practiceNew treatmentsGlucose monitoringInfusion pumpInsulin deliveryT1DDiabetesTreatmentSuspension device1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation
SCHIAVON M, GALDERISI A, KRAEMER K, COBELLI C, MAN C, CENGIZ E. 1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation. Diabetes 2019, 68 DOI: 10.2337/db19-1054-p.Peer-Reviewed Original ResearchContinuous glucose monitoringInsulin sensitivityType 1 diabetesEuropean Medical Information FrameworkInsulin pump dataClosed-loop treatmentOral minimal modelMannKind CorporationSequential mealsInsulin therapyMeal studyPlasma glucoseGlycemic outcomesType 1Glucose monitoringSpeakers bureauMeal variationT1D.T1DInternational SocietyAdvisory PanelPump dataTreatmentSI indexDiabetes
2018
Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy
SIEBEL S, PATEL N, GALDERISI A, CARRIA L, TAMBORLANE W, SHERR J. Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy. Diabetes 2018, 67 DOI: 10.2337/db18-117-lb.Peer-Reviewed Original ResearchPlasma glucoseSGLT2i useBHB levelsMedtronic MiniMedBoehringer Ingelheim GmbHSGLT2 inhibitor therapyInterruption studiesRapid-acting insulinType 1 diabetesRisk of DKABasal insulin infusionEli LillySuppression of ketogenesisCanagliflozin therapyRescue doseSGLT2i therapySGLT2i treatmentBasal insulinInhibitor therapySGLT2 inhibitorsT1D patientsAdjunctive agentsMetabolic decompensationInsulin infusionJanssen Pharmaceuticals
2017
Metabolomics reveals new metabolic perturbations in children with type 1 diabetes
Galderisi A, Pirillo P, Moret V, Stocchero M, Gucciardi A, Perilongo G, Moretti C, Monciotti C, Giordano G, Baraldi E. Metabolomics reveals new metabolic perturbations in children with type 1 diabetes. Pediatric Diabetes 2017, 19: 59-67. PMID: 28401628, DOI: 10.1111/pedi.12524.Peer-Reviewed Original ResearchConceptsBody mass indexType 1 diabetesHealthy controlsPubertal statusExcess of cortisolMetabolome of childrenPediatric diabetes clinicMacrovascular complicationsDiabetes clinicDisease durationNeuronal damagePediatric patientsClinical featuresMass indexCase groupTryptophan catabolitesHealthy peersUrinary metabolitesUrinary samplesBacterial productsT1DUntargeted metabolomics approachMetabolic perturbationsDiabetesPatients
2016
High frequency of diabetic ketoacidosis at diagnosis of type 1 diabetes in Italian children: a nationwide longitudinal study, 2004–2013
Cherubini V, Skrami E, Ferrito L, Zucchini S, Scaramuzza A, Bonfanti R, Buono P, Cardella F, Cauvin V, Chiari G, d′Annunzio G, Frongia A, Iafusco D, Patera I, Toni S, Tumini S, Rabbone I, Lombardo F, Carle F, Gesuita R, Lera R, De Luna L, Gualtieri A, Zecchino C, Piccinno E, Reinstadler P, Prandi E, Gallo F, Morganti G, Ripoli C, La Loggia A, Scanu P, Cardinale G, Tomaselli L, Citriniti F, Lazzaro N, De Donno V, Mainetti B, Coccioli M, Maccioni R, Marongiu U, Bruzzese M, Iannilli A, Pardi D, Confetto S, Zanfardino A, Iughetti L, Franzese A, Cadario F, Milia A, Piredda G, Soro M, Correddu A, Galderisi A, De Berardinis F, Federico G, Zanette G, Suprani T, Pedini A, Bitti M, Delvecchio M, Trada M, Meloni G, Gaiero A, Bulciolu P, Guerraggio L, Faleschini E, Zanatta M, Salvatoni A, Maffeis C, Arnaldi C. High frequency of diabetic ketoacidosis at diagnosis of type 1 diabetes in Italian children: a nationwide longitudinal study, 2004–2013. Scientific Reports 2016, 6: 38844. PMID: 27991500, PMCID: PMC5171855, DOI: 10.1038/srep38844.Peer-Reviewed Original ResearchConceptsSevere diabetic ketoacidosisDiabetic ketoacidosisType 1 diabetesDKA frequencyAge groupsLongitudinal population-based studyType 1 diabetes diagnosisMultiple logistic regression modelPopulation-based studyNationwide longitudinal studyYears of ageLogistic regression modelsItalian childrenFamily historyHigh riskMild/Diabetes diagnosisKetoacidosisHealthcare strategiesYoung age childrenDiabetesEarly detectionDiagnosisLongitudinal studyTime trendsRandomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe
Del Favero S, Boscari F, Messori M, Rabbone I, Bonfanti R, Sabbion A, Iafusco D, Schiaffini R, Visentin R, Calore R, Moncada Y, Galasso S, Galderisi A, Vallone V, Di Palma F, Losiouk E, Lanzola G, Tinti D, Rigamonti A, Marigliano M, Zanfardino A, Rapini N, Avogaro A, Chernavvsky D, Magni L, Cobelli C, Bruttomesso D. Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. Diabetes Care 2016, 39: 1180-1185. PMID: 27208335, DOI: 10.2337/dc15-2815.Peer-Reviewed Original ResearchConceptsSensor-augmented pumpCrossover trialMean glucoseArtificial pancreasType 1 diabetesArtificial Pancreas ProjectWearable artificial pancreasAP trialOlder childrenTrialsHypoglycemiaYoung childrenChildrenPancreasOvernight timeSignificant changesGlucoseDaysDiabetesOutpatientsResearch designThreefold reduction
2015
Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes
Lipes M, Galderisi A. Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes. Current Diabetes Reports 2015, 15: 30. PMID: 25821130, PMCID: PMC4376963, DOI: 10.1007/s11892-015-0598-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseHeart diseaseChronic myocardial inflammationPoor CVD outcomesUnderstanding of CVDType 1 diabetesCardiac autoimmunityMicrovascular complicationsCVD outcomesMyocardial inflammationClinical evidenceHeart syndromeExcess mortalityClinical studiesNovel biomarkersT1DTherapeutic implicationsTherapeutic targetType 2Type 1Same diseaseT2D.DiseaseDiagnostic assaysT1D.
2014
An easy, fast, effective tool to monitor the incidence of type 1 diabetes among children aged 0–4 years in Italy: the Italian Hospital Discharge Registry (IHDR)
Vichi M, Iafusco D, Galderisi A, Stazi M, Nisticò L. An easy, fast, effective tool to monitor the incidence of type 1 diabetes among children aged 0–4 years in Italy: the Italian Hospital Discharge Registry (IHDR). Acta Diabetologica 2014, 51: 287-294. PMID: 24473635, DOI: 10.1007/s00592-014-0556-4.Peer-Reviewed Original ResearchConceptsType 1 diabetes incidenceType 1 diabetesHospital Discharge RegistryDiabetes incidenceDischarge RegistryFirst hospitalizationFirst hospitalization ratesPublic health purposesIncident hospitalizationHospitalization ratesCalendar periodPrevalent casesFirst episodeHospitalizationDiabetesOverall populationNational ratesIncidenceAge rangeYear residentsHealth purposesNational dataRegistryRecord linkage procedureChildren
2012
Emerging Effects of Early Environmental Factors over Genetic Background for Type 1 Diabetes Susceptibility: Evidence from a Nationwide Italian Twin Study
Nisticò L, Iafusco D, Galderisi A, Fagnani C, Cotichini R, Toccaceli V, Stazi M, Endocrinology and Diabetology T. Emerging Effects of Early Environmental Factors over Genetic Background for Type 1 Diabetes Susceptibility: Evidence from a Nationwide Italian Twin Study. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: e1483-e1491. PMID: 22569240, DOI: 10.1210/jc.2011-3457.Peer-Reviewed Original ResearchConceptsProband-wise concordanceType 1 diabetes susceptibilityDiabetic twinsDiabetes susceptibilityRecurrence riskPediatric diabetes care centersRecent onset casesDiabetes care centerKaplan-Meier methodZinc transporter 8Type 1 diabetesEarly postnatal lifeEarly environmental factorsMean ageCare centerDiabetes recordsProband diagnosisPostnatal lifeTransporter 8Twin cohortType 1Median yearsDiagnosisTwin RegistryDizygotic pairs
2011
Chat Line for Adolescents with Type 1 Diabetes: A Useful Tool to Improve Coping with Diabetes: A 2-Year Follow-Up Study
Iafusco D, Galderisi A, Nocerino I, Cocca A, Zuccotti G, Prisco F, Scaramuzza A. Chat Line for Adolescents with Type 1 Diabetes: A Useful Tool to Improve Coping with Diabetes: A 2-Year Follow-Up Study. Diabetes Technology & Therapeutics 2011, 13: 551-555. PMID: 21406010, DOI: 10.1089/dia.2010.0188.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdolescentAdolescent BehaviorAttitude to HealthChildChild BehaviorDiabetes Mellitus, Type 1FemaleFollow-Up StudiesGlycated HemoglobinHealth BehaviorHumansInternetItalyMalePatient CompliancePatient Education as TopicQuality of LifeReproducibility of ResultsSelf CareSurveys and Questionnaires